Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Berlin - Delayed Quote • EUR Corcept Therapeutics Inc (HTD.BE) Follow Add holdings 62.84 +2.64 +(4.39%) At close: April 25 at 8:08:16 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for HTD.BE 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: HTD.BE View More All News Press Releases SEC Filings 3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?